Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody-Drug Conjugates.

Zhao H, Atkinson J, Gulesserian S, Zeng Z, Nater J, Ou J, Yang P, Morrison K, Coleman J, Malik F, Challita-Eid P, Karki S, Aviña H, Hubert R, Capo L, Snyder J, Moon SJ, Luethy R, Mendelsohn BA, Stover DR, Doñate F.

Cancer Res. 2018 Apr 15;78(8):2115-2126. doi: 10.1158/0008-5472.CAN-17-3202. Epub 2018 Jan 30.

2.

Inhibition of Megakaryocyte Differentiation by Antibody-Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia.

Zhao H, Gulesserian S, Ganesan SK, Ou J, Morrison K, Zeng Z, Robles V, Snyder J, Do L, Aviña H, Karki S, Stover DR, Doñate F.

Mol Cancer Ther. 2017 Sep;16(9):1877-1886. doi: 10.1158/1535-7163.MCT-16-0710. Epub 2017 Jun 27.

3.

A Potential Mechanism for ADC-Induced Neutropenia: Role of Neutrophils in Their Own Demise.

Zhao H, Gulesserian S, Malinao MC, Ganesan SK, Song J, Chang MS, Williams MM, Zeng Z, Mattie M, Mendelsohn BA, Stover DR, Doñate F.

Mol Cancer Ther. 2017 Sep;16(9):1866-1876. doi: 10.1158/1535-7163.MCT-17-0133. Epub 2017 May 18.

4.

The Discovery and Preclinical Development of ASG-5ME, an Antibody-Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer.

Mattie M, Raitano A, Morrison K, Morrison K, An Z, Capo L, Verlinsky A, Leavitt M, Ou J, Nadell R, Aviña H, Guevara C, Malik F, Moser R, Duniho S, Coleman J, Li Y, Pereira DS, Doñate F, Joseph IB, Challita-Eid P, Benjamin D, Stover DR.

Mol Cancer Ther. 2016 Nov;15(11):2679-2687. Epub 2016 Aug 22.

5.

Preclinical Evaluation of an Anti-Nectin-4 ImmunoPET Reagent in Tumor-Bearing Mice and Biodistribution Studies in Cynomolgus Monkeys.

Campbell DO, Noda A, Verlinsky A, Snyder J, Fujita Y, Murakami Y, Fushiki H, Miyoshi S, Lacayo S, Cabral E, Yang P, Stover DR, Joseph IB.

Mol Imaging Biol. 2016 Oct;18(5):768-75. doi: 10.1007/s11307-016-0953-x.

PMID:
27122234
6.

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.

Challita-Eid PM, Satpayev D, Yang P, An Z, Morrison K, Shostak Y, Raitano A, Nadell R, Liu W, Lortie DR, Capo L, Verlinsky A, Leavitt M, Malik F, Aviña H, Guevara CI, Dinh N, Karki S, Anand BS, Pereira DS, Joseph IB, Doñate F, Morrison K, Stover DR.

Cancer Res. 2016 May 15;76(10):3003-13. doi: 10.1158/0008-5472.CAN-15-1313. Epub 2016 Mar 24.

7.

Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker.

Morrison K, Challita-Eid PM, Raitano A, An Z, Yang P, Abad JD, Liu W, Lortie DR, Snyder JT, Capo L, Verlinsky A, Aviña H, Doñate F, Joseph IB, Pereira DS, Morrison K, Stover DR.

Mol Cancer Ther. 2016 Jun;15(6):1301-10. doi: 10.1158/1535-7163.MCT-15-0570. Epub 2016 Mar 4.

8.

AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma.

Doñate F, Raitano A, Morrison K, An Z, Capo L, Aviña H, Karki S, Morrison K, Yang P, Ou J, Moriya R, Shostak Y, Malik F, Nadell R, Liu W, Satpayev D, Atkinson J, Joseph IB, Pereira DS, Challita-Eid PM, Stover DR.

Clin Cancer Res. 2016 Apr 15;22(8):1989-99. doi: 10.1158/1078-0432.CCR-15-1542. Epub 2015 Nov 20.

9.

AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML.

Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR.

Mol Cancer Ther. 2015 Jul;14(7):1650-60. doi: 10.1158/1535-7163.MCT-15-0067. Epub 2015 May 1.

10.

Discoidin domain receptor 1 contributes to tumorigenesis through modulation of TGFBI expression.

Rudra-Ganguly N, Lowe C, Mattie M, Chang MS, Satpayev D, Verlinsky A, An Z, Hu L, Yang P, Challita-Eid P, Stover DR, Pereira DS.

PLoS One. 2014 Nov 4;9(11):e111515. doi: 10.1371/journal.pone.0111515. eCollection 2014.

11.

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC.

Blood. 2009 Jul 9;114(2):371-9. doi: 10.1182/blood-2008-11-191577. Epub 2009 May 5.

12.

Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.

Heath DJ, Chantry AD, Buckle CH, Coulton L, Shaughnessy JD Jr, Evans HR, Snowden JA, Stover DR, Vanderkerken K, Croucher PI.

J Bone Miner Res. 2009 Mar;24(3):425-36. doi: 10.1359/jbmr.081104.

13.

TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2.

Natoni A, MacFarlane M, Inoue S, Walewska R, Majid A, Knee D, Stover DR, Dyer MJ, Cohen GM.

Br J Haematol. 2007 Nov;139(4):568-77. Epub 2007 Oct 8.

PMID:
17922877
14.

Novel magnetic supports for small molecule affinity capture of proteins for use in proteomics.

Sucholeiki I, Toledo-Sherman LM, Hosfield CM, Boutilier K, DeSouza LV, Stover DR.

Mol Divers. 2004;8(1):9-19.

PMID:
14964784
15.

Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure.

Suñé C, Brennan L, Stover DR, Klimkait T.

Clin Microbiol Infect. 2004 Feb;10(2):119-26.

16.

Mechanisms and kinetics of procathepsin D activation.

Wittlin S, Rösel J, Hofmann F, Stover DR.

Eur J Biochem. 1999 Oct 1;265(1):384-93.

17.

Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors.

Zhu X, Kim JL, Newcomb JR, Rose PE, Stover DR, Toledo LM, Zhao H, Morgenstern KA.

Structure. 1999 Jun 15;7(6):651-61.

18.

Recent advances in protein kinase inhibition: current molecular scaffolds used for inhibitor synthesis.

Stover DR, Lydon NB, Nunes JJ.

Curr Opin Drug Discov Devel. 1999 Jul;2(4):274-85.

PMID:
19649955
19.
20.
21.
22.

Cdc2-mediated modulation of pp60c-src activity.

Stover DR, Liebetanz J, Lydon NB.

J Biol Chem. 1994 Oct 28;269(43):26885-9.

23.
24.
25.

Protein-tyrosine-phosphatase CD45 is phosphorylated transiently on tyrosine upon activation of Jurkat T cells.

Stover DR, Charbonneau H, Tonks NK, Walsh KA.

Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7704-7.

Supplemental Content

Loading ...
Support Center